the mortality rate for cardiogenic shock has decreased over the past decade. these improvements are presumed to reflect increased use of intraaortic ballon counterpulsation and coronary reperfusion strategies which, by restoring patency to the infarct-related artery, can limit infarct size. despite ...
The benefit of pharmacological thrombolysis in patients with cardiogenic shock due to pulmonary embolism has demonstrated reductions of mortality. However, both systemic thrombolysis and endovascular therapy in patients without shock remains a controversial issue that justifies current research. We report the...